All In Biotech

Drug Trial Radar · NCT06009991

The Dose Range of Remimazolam Besylate in Different Age Groups

The Investigation of the Dose Range of Remimazolam Besylate in Different Age Groups of Adults and Its Effects on Hemodynamics

Last checked: Nov 20, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,876 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,876

Planned (sponsor's estimate)

Start

Jul 17, 2023

Primary completion

Sep 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Renmin Hospital of Wuhan University; Wuhan University; The General Hospital of Central Theater Command; Taihe Hospital; Yichang Central People's Hospital; Jingzhou Central Hospital; Beijing Shijitan Hospital, Capital Medical University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; First Affiliated Hospital of Fujian Medical University; Tianjin Nankai Hospital; Sichuan Provincial People's Hospital; Shanxi Bethune Hospital
First posted
Aug 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, parallel, controlled clinical study of patients at different ages underwent elective non-cardiac surgery under general anesthesia. The aim of this study is to explore the dose range of remimazolam besylate for patients at different ages, to provide guidance for anesthesia induction and maintenance of remimazolam besylate. And to investigate the incidence of perioperative hypotension and postoperative related organ dysfunction in patients received total intravenous anesthesia with remimazolam besylate, compared with propofol.

Conditions

  • Remimazolam
  • Anesthesia

Interventions

  • Remimazolam besylateDrug

    Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need). Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).

  • PropofolDrug

    Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance. Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of intraoperative hypotensionTime frame: Operation 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ongji Hospital, Tongji Medical College, Huazhong Science and Technology University

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.